Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Kura Oncology (KURA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 509,736
  • Shares Outstanding, K 38,040
  • Annual Sales, $ 0 K
  • Annual Income, $ -35,430 K
  • 36-Month Beta 4.41
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.85

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate -0.42
  • Number of Estimates 6
  • High Estimate -0.40
  • Low Estimate -0.46
  • Prior Year -0.37
  • Growth Rate Est. (year over year) -13.51%

Price Performance

See More
Period Period Low Period High Performance
1-Month
11.01 +22.98%
on 11/28/18
14.48 -6.49%
on 12/04/18
+1.55 (+12.93%)
since 11/09/18
3-Month
10.20 +32.75%
on 10/24/18
19.25 -29.66%
on 09/11/18
-5.36 (-28.36%)
since 09/10/18
52-Week
10.20 +32.75%
on 10/24/18
24.02 -43.64%
on 02/20/18
-1.36 (-9.13%)
since 12/08/17

Most Recent Stories

More News
Kura Oncology Announces Proof of Concept in Angioimmunoblastic T-Cell Lymphoma, Validation of CXCL12 as a Therapeutic Target of Tipifarnib in Peripheral T-Cell Lymphoma

- Two CRs, four PRs (46% ORR) observed in advanced AITL patients in Phase 2 trial of tipifarnib in PTCL -

KURA : 13.50 (+0.75%)
Report: Exploring Fundamental Drivers Behind J.B. Hunt Transport Services, Kura Oncology, National Beverage, Benefitfocus, PTC Therapeutics, and Walgreens Boots Alliance -- New Horizons, Emerging Trends, and Upcoming Developments

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of J.B. Hunt Transport Services,...

PTCT : 33.91 (+1.65%)
FIZZ : 85.14 (+1.74%)
BNFT : 51.49 (+1.70%)
JBHT : 98.87 (-0.97%)
WBA : 80.33 (-1.06%)
KURA : 13.50 (+0.75%)
Kura Oncology Announces New Patent for Tipifarnib in Angioimmunoblastic T-Cell Lymphoma

- AITL patent expands protection for tipifarnib, provides exclusivity in U.S. to 2037 -

KURA : 13.50 (+0.75%)
Kura Oncology Adds Commercial Veteran Mary Szela to Board of Directors

Ms. Szela brings expertise in global brand development to Kura as company enters first registration-directed trial

KURA : 13.50 (+0.75%)
Kura Oncology: 3Q Earnings Snapshot

SAN DIEGO (AP) _ Kura Oncology Inc. (KURA) on Monday reported a loss of $15 million in its third quarter.

KURA : 13.50 (+0.75%)
Kura Oncology Reports Third Quarter 2018 Financial Results and Provides Corporate Update

- Registration-directed trial of tipifarnib in HRAS mutant HNSCC now underway -

KURA : 13.50 (+0.75%)
Kura Oncology Initiates Registration-Directed Trial of Tipifarnib in HRAS Mutant Head and Neck Squamous Cell Carcinomas

- AIM-HN designed to enroll at least 59 patients with HRAS mutant HNSCC -

KURA : 13.50 (+0.75%)
Kura Oncology Announces Upcoming Presentations at ASH Annual Meeting

Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that two abstracts related to the company's...

KURA : 13.50 (+0.75%)
Kura Oncology to Report Third Quarter 2018 Financial Results

Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that it will report third quarter 2018 financial...

KURA : 13.50 (+0.75%)
Factors of Influence in 2018, Key Indicators and Opportunity within Dropbox, Kura Oncology, DHT, Wayfair, US Foods Holding, and InflaRx N.V -- New Research Emphasizes Economic Growth

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Dropbox, Inc. (NASDAQ:DBX),...

DHT : 4.20 (-3.67%)
IFRX : 29.50 (-1.07%)
W : 105.89 (+1.07%)
KURA : 13.50 (+0.75%)
DBX : 21.70 (+0.88%)
USFD : 31.72 (-0.35%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

See More Share

Trade KURA with:

Business Summary

Kura Oncology, Inc. is a biopharmaceutical company. The company is involved in the discovery and development of therapeutics for the treatment of tumors and blood cancers. Its product pipeline includes small molecule drug candidates which are in different clinical trial consists of Tipifarnib-HRAS, Tipifarnib-PTCL,...

See More

Key Turning Points

2nd Resistance Point 14.22
1st Resistance Point 13.81
Last Price 13.50
1st Support Level 13.05
2nd Support Level 12.70

See More

52-Week High 24.02
Fibonacci 61.8% 18.74
Fibonacci 50% 17.11
Fibonacci 38.2% 15.48
Last Price 13.50
52-Week Low 10.20

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar